Table 6.
The top 10 pathway enrichment of upregulated differentially expressed host linear transcripts affected by EA intervention.
| Pathway | Selection counts | P | False discovery rate | Differentially expressed genes |
|---|---|---|---|---|
| Thyroid hormone signaling pathway | 5 | <0.05 | <0.05 | MED13, MED13L, NCOA2, PIK3CB, SLC16A10 |
| Glycosphingolipid biosynthesis-ganglio series | 2 | <0.05 | <0.05 | ST3GAL5, ST6GALNAC3 |
| cGMP-PKG signaling pathway | 4 | <0.05 | <0.05 | ADCY9, PDE5A, PIK3CB, ROCK1 |
| Transcriptional misregulation in cancer | 4 | <0.05 | <0.05 | ETV6, MLLT3, TGFBR2, ZEB1 |
| Choline metabolism in cancer | 3 | <0.05 | <0.05 | PCYT1A, PDGFD, PIK3CB |
| Rap1 signaling pathway | 4 | <0.05 | <0.05 | ADCY9, FYB, PDGFD, PIK3CB |
| Regulation of actin cytoskeleton | 4 | <0.05 | <0.05 | IQGAP2, PDGFD, PIK3CB, ROCK1 |
| AMPK signaling pathway | 3 | <0.05 | <0.05 | ACACA, PIK3CB, RAB14 |
| Platelet activation | 3 | <0.05 | <0.05 | ADCY9, PIK3CB, ROCK1 |
| Regulation of lipolysis in adipocytes | 2 | <0.05 | <0.05 | ADCY9, PIK3CB |